Development of matrix metalloproteinase inhibitors in cancer therapy

Journal of the National Cancer Institute

Volumn 93, Issue 3, 2001, Pages 178-193

  Hidalgo, Manuel ^a,c   Eckhardt, S Gail ^b  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; BATIMASTAT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CGS 27023A; CLODRONIC ACID; DOXYCYCLINE; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PACLITAXEL; PRINOMASTAT; REBIMASTAT; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TANOMASTAT; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVALENT BOND; CYTOSTASIS; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOUSE; MUSCULOSKELETAL DISEASE; NONHUMAN; ONCOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TOXICITY; TUMOR GROWTH;

EID: 0035819527     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.3.178     Document Type: Review

References (190)

1. Changing views of the role of matrix metalloproteinases in metastasis
2. Matrix metalloproteinases and their inhibitors in tumour growth and invasion
3. Gelatinase A activity directly modulates melanoma cell adhesion and spreading
4. Matrix metalloproteinases and metastasis
5. Matrix metalloproteinase inhibitors: Present achievements and future prospects
6. Matrix metalloproteinase inhibitors
7. Clinical studies with matrix metalloproteinase inhibitors
8. Regulation of matrix metalloproteinase gene expression
9. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
10. Stimulation of gelatinase B and tissue inhibitors of metalloproteinase (TIMP) production in co-culture of human osteosarcoma cells and human fibroblasts: Gelatinase B production was stimulated via up-regulation of factor (FGF) receptor
11. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells
12. In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines
13. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
14. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9
15. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells
16. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion
17. EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP
18. Transforming growth factor betal acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells
19. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane
20. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: Implication of ICAM-1
21. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells
22. Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion
23. Mechanism for pro matrix metalloproteinase activation
24. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
25. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation
26. Endoproteinase-protein inhibitor interactions
27. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation
28. IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression
29. Up-regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in articular chondrocytes is mediated by serine/threonine and tyrosine kinases
30. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion
31. TIMP-2 growth-stimulatory activity: A concentration and cell type-specific response in the presence of insulin
32. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice
33. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3
34. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression
35. Membrane-type matrix metalloproteinase
36. An odyssey from breast to bone: Multi-step control of mammary metastases and osteolysis by matrix metalloproteinases
37. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
38. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells
39. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system
40. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A
41. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay
42. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice
43. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
44. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
45. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy
46. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1
47. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3
48. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix
49. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma
50. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate
51. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis
52. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells
53. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses
54. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application
55. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications
56. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types
57. Expression of collagenase-3 (matrix metalloproteinase-13) is squamous cell carcinoma of the head and neck
58. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions
59. Expression of most matrix metalloproteinases family members in breast cancer represents a tumor-induced host response
60. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas
61. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas
62. 'Proteolytic switching': Opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression
63. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas
64. Different expression patterns of MMP-2 and MMP-9 in breast cancer
65. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer
66. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
67. Association of matrylisin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma
68. Matrilysin in early stage intestinal tumorigenesis
69. Inhibition of tumor promoter activity toward mouse fibroblasts and their in vitro transformation by tissue inhibitor of metalloproteinases-1 (TIMP-1)
70. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line
71. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth
72. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinase (TIMPs) in human pancreatic carcinoma
73. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases
74. TIMP-1 and adverse prognosis in non-small cell lung cancer
75. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma
76. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis
77. Enhanced RNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human breast cancer
78. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas
79. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer
80. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion
81. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase, on urokinase expression and in vitro invasion
82. Matrylysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model
83. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinase-3 inhibits invasion and induces apoptosis in melanoma cells
84. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinase-3 (TIMP-3)
85. Matrix metalloproteinase inhibitors
86. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile
87. Matrix metallo-proteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
88. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20
89. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
90. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo
91. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinases
92. Inhibition of organ invasion by matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
93. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94)
94. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells
95. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
96. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice
97. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian cancer
98. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma
99. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer
100. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
101. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites
102. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
103. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers
104. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
105. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
106. Phase I-II study of marimastat (BB2516) in patients (pts) with metastatic melanomas
107. Phase IB study of concurrent administration of marimatat and gemcitabine in non-resectable pancreatic cancer
108. Schedules of 5-FU and the matrix metalloproteinase inhibitor marimastat (MAR): A phase I study
109. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapse ovarian cancer
110. Pilot pharmacokinetic study of marimastat (MAR) in combination with carboplatin (C)/paclitaxel (T) in patients with metastatic or locally advanced inoperable non-small cell lung cancer (NSCLC)
111. Marimastat (BB2516): Current status of development
112. Phase I/+ pharmacokinetic evaluation of marimastat in patients (pts) with advanced prostate cancer (PC): Identification of the biological active dose
113. A randomized phase II pilot trial of adjuvant marimastat (MAR) in patients (pts) with early breast cancer
114. Combined analysis of studies of the effects of the matrix metallo- proteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer- term studies
115. Matrix metalloproteinase: Biologic activity and clinical implications
116. A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer
117. A randomized double-blind placebo controlled study of marimastat in patients with inoperable gastric adenocarcinoma
118. Bay 12-9566, a novel byphenyl matrix metalloproteinase inhibitor, demonstrated anti-invasive and anti-angiogenic properties
119. Activity of the biphenyl matrix metalloproteinase inhibitor Bay 12-9566 in murine in vivo models
120. Anti-metastatic activity of Bay 12-9566 in a human colon carcinoma HCT116 orthotopic model
121. Inhibition of human breast cancer regrowth and pulmonary metastasis by Bay 12-9566 in athymic mice
122. Preclinical drug safety profile for the antimetastatic matrix metalloproteinase inhibitor agent Bay 12-9566
123. [14C] Bay 12-9566: Assessment of enterohepatic cycling in male rats following intraduodenal administration
124. Pharmacokinetics of Bay 12-9566 in guinea pigs following intravenous and oral administration
125. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
126. Clinical pharmacology of the metalloproteinase (MMP) and angiogenesis inhibitor Bayer 12-9566 in cancer patients
127. Phase I study of Bay 12-9566-a matrix metalloproteinase inhibitor (MMPI)
128. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI, Bay 12-9566)
129. A phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor Bay 12-9566 in combination with paclitaxel and carboplatin
130. Pharmacokinetics of Bay 12-9566: Early results of a Canadian phase I dose escalation study in cancer patients
131. Preclinical and clinical pharmacology of matrix metalloproteinase inhibitor (MMPIs)
132. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (pts) with advanced pancreatic cancer
133. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
134. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
135. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations and not total daily dose, exposure or peak plasma concentrations
136. Marked antiangiogenic and antitumor efficacy of AG3340 in chemo-resistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
137. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
138. A phase I study of AG3340, a matrix metalloproteinase (MMP) inhibitor in patients having advanced cancer
139. Phase I study of AG3340, a matrix metalloproteinase inhibitor in combination with mitoxantrone/prednisone in patients having advanced prostate cancer
140. Phase I study of the matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors
141. Promising new developments in cancer chemotherapy
142. CGS 27023A, a potent and orally active matrix metalloprotease inhibitor with antitumor activity
143. Matrix metalloproteinase inhibitor (MMPI) CGS27023A inhibited extravasation of B16-F10 melanoma cells in the experimental metastatic model
144. A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor
145. Tetracyclines inhibit connective tissue breakdown by multiple non- antimicrobial mechanisms
146. MMP inhibition in prostate cancer
147. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells
148. Chemically modified tetracylines inhibit human melanoma cell invasion and metastasis
149. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation
150. Matrix metalloproteinases and their inhibition in periodontal treatment
151. Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease
152. The tetracyclines analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase mechanism
153. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: Relationship to structure of the enzyme
154. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells
155. Effects of doxycycline on human prostate cancer cells in vitro
156. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells
157. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice
158. A phase I trial of doxycycline (Doxy) in patients with cancer
159. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer
160. Protracted daily treatment with Col-3, and oral tetracycline analog, matrix metalloproteinase (MMP) inhibitor, is feasible: A phase I pharmacokinetic and biological study
161. A phase I clinical trial of oral Col-3, a matrix metalloproteinase inhibitor, administered daily in patients with refractory metastatic cancer
162. Bisphosphonates in the treatment of bone diseases
163. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
164. Bisphosphonates: Mechanism of action
165. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice
166. Alendronate blocks TGF-betal stimulated collagen 1 degradation by human prostate PC-3 ML cells
167. MMP inhibition and downregulation by bisphosphonates
168. Anti-cancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?
169. Determination of gelatinase-A (MMP-2) activity using a novel immunocapture assay
170. MMP-9 activity in urine from patients with various tumors as measured by a novel MMP activity assay using modified urokinase as a substrate
171. Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin
172. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for an in vivo tyrosine kinase inhibition
173. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways
174. There are no bad anticancer drugs, only bad clinical trial designs- twenty-first Richard and Hinda Rosenthal Foundation Award Lecture
175. Phase I and II trials of novel anticancer agents: Endpoints, efficacy and existentialism
176. Randomized discontinuation trials: Utility and efficiency
177. Design and synthetic considerations of matrix metalloproteinase inhibitors
178. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
179. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
180. Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice
181. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives
182. Inhibition of spontaneous rat osteosarcoma lung metastasis by 3S-[4- (N- hydroxyamino)-2R-isobutylsuccinyl]amino-1-methoxy-3,4-dihydroc arbostyril, a novel matrix metalloproteinase inhibitor
183. Solution structures of stromelysin complexed to thiadiazole inhibitors
184. Tumor targeting with a selective gelatinase inhibitor
185. Preclinical and clinical studies of MMP inhibitors in cancer
186. Membrane protein secretases
187. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line
188. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures
189. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor
190. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma